Adeia Wins Best of Show Award at FMS: The Future of Memory and Storage Conference

Rhea-AI Summary

Niagen Bioscience (NASDAQ: NAGE) has published groundbreaking clinical study results in Aging Cell, demonstrating the efficacy of their patented nicotinamide riboside (NR) ingredient, Niagen®, in treating Werner syndrome (WS), a rare genetic aging disorder. The 52-week randomized, double-blind, placebo-controlled crossover trial showed that daily 1,000mg Niagen supplementation increased NAD+ levels by approximately 140% and improved cardiovascular and skin health markers.

Key findings include improved arterial stiffness, beneficial changes in HDL particles, and reduced skin ulcer size. The study involved nine individuals with WS, with no moderate or severe adverse events reported. This research expands Niagen's rare disease portfolio, which includes promising results in Ataxia Telangiectasia (AT), where the FDA has granted both Orphan Drug Designation and Rare Pediatric Disease Designation.

Positive

• Clinical trial demonstrated ~140% increase in plasma NAD+ levels vs. placebo
• Significant improvements in cardiovascular markers and skin health
• FDA granted Orphan Drug and Rare Pediatric Disease Designations for Ataxia Telangiectasia
• Strong safety profile with fewer adverse events in treatment group vs. placebo
• Successful expansion into rare disease therapeutic applications

Negative

• Small trial size with only 9 participants limits statistical significance
• Mild liver enzyme elevations noted in some participants

SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adeia Inc., a leading innovator in semiconductor 3D integration and advanced packaging technologies, is proud to announce that it has been presented with the “Most Innovative Technology” award, which is a “Best of Show” award – one of the highest honors recognizing outstanding achievement and innovation – at FMS: the Future of Memory and Storage. FMS is recognized as the world's foremost conference highlighting the key advancements, trends, and industry figures shaping the multi-billion-dollar high-speed memory, storage, and SSD markets. This esteemed recognition highlights Adeia’s commitment to excellence and innovation in hybrid bonding and advanced interconnect solutions.

The “Most Innovative Technology” award is given to the most outstanding innovation showcased at FMS. Adeia received this honor for its groundbreaking hybrid bonding technology enabling 3D integration of electronic systems with improved interconnect density, speed, power efficiency, and reliability in NAND, DRAM and logic products. This novel, scalable interconnect technology is fueling leading semiconductor roadmaps.

“Vertical stacking has become an innovative architectural technique leading to the creation of 3D NAND and 3D DRAM technologies and has significantly increased storage capacity within the same footprint for applications such as AI workloads requiring high performance and vast amounts of data storage in a small footprint,” said Jay Kramer, Chair of the Awards Program and President of Network Storage Advisors Inc. “We are proud to recognize Adeia’s hybrid bonding technology, an enabler for greater interconnect density, speed, power efficiency and enhanced reliability in NAND, DRAM and logic products. Adeia hybrid bonding helps overcome the "memory wall" by providing faster and more efficient data transfer between the processor and memory.”

“We are honored to receive the 'Most Innovative Technology' award at FMS,” said Dana Escobar, Chief Licensing Officer and General Manager, Semiconductor at Adeia. “This award is a testament to the incredible work of our team and Adeia’s commitment to solving important integration challenges for our customers. Hybrid bonding is more than a novel technology – it's a foundation for the next era of memory and logic performance.”

Adeia’s die-to-wafer and wafer-to-wafer hybrid bonding technology supports submicron interconnect pitch, unlocking the full potential of chiplet architectures and heterogeneous integration. Memory and logic can now be contiguously integrated, reducing latency, increasing bandwidth, and improving power efficiency in applications including AI workloads of sorting, high performance computing, and edge compute for datacenter, mobile, and automotive.

Held annually in August in the heart of Silicon Valley, FMS: the Future of Memory and Storage is the premier memory and storage event attracting top professionals, innovators, and companies from around the world.

For more information about FMS, please visit FutureMemoryStorage.com.

For more information about Adeia and its award-winning hybrid bonding technology, please visit www.adeia.com.

About Adeia

Adeia is a leading R&D and intellectual property (IP) licensing company that accelerates the adoption of innovative technologies in the media and semiconductor industries. Adeia’s fundamental innovations underpin technology solutions that are shaping and elevating the future of digital entertainment and electronics. Adeia’s IP portfolios power the connected devices that touch the lives of millions of people around the world every day as they live, work and play. For more, please visit www.adeia.com.

About FMS: the Future of Memory and Storage

FMS: the Future of Memory and Storage, produced by Conference ConCepts, is the premier global event showcasing cutting-edge developments in multi-billion-dollar high-speed memory and storage technologies. As the world’s largest conference and exhibition in this sector, FMS highlights mainstream applications, breakthrough innovations, key enabling technologies, and the full spectrum of players—from leading vendors to disruptive startups. This event spans critical application areas including AI, enterprise data centers, high-performance computing, mobile devices at the edge, and embedded systems. FMS serves as a dynamic hub where technology professionals, executive leaders, customers, cloud providers, hyperscaler companies, and industry analysts converge to explore the evolving landscape of memory and storage. With a renewed commitment to inclusivity and innovation, FMS is shaping the future of storage—especially at its intersection with artificial intelligence.

Adeia Investor Contact:
Chris Chaney
Vice President, Investor Relations
IR@adeia.com

FMS Contact:
Michelle Suzuki, Public Relations & Analysts for FMS
michelle@msc-pr.com
+1 310.444.7115

FAQ

What were the key results of Niagen's Werner Syndrome clinical trial?

The trial showed a 140% increase in NAD+ levels, improved arterial stiffness, beneficial changes in HDL particles, and reduced skin ulcer size. The treatment demonstrated a strong safety profile with no moderate or severe adverse events.

How many patients participated in NAGE's Werner Syndrome study?

The study included 9 participants with Werner Syndrome, with a mean age of 47, in a 52-week randomized, double-blind, placebo-controlled crossover trial.

What FDA designations has Niagen Bioscience received for rare diseases?

Niagen has received Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation from the FDA for the treatment of Ataxia Telangiectasia.

What is the dosage of Niagen used in the Werner Syndrome clinical trial?

Participants received 1,000 mg/day of Niagen or placebo for 26 weeks before crossing over to the alternate treatment for an additional 26 weeks.

What is Werner Syndrome and how rare is it?

Werner Syndrome is a rare genetic disorder causing rapid aging and premature mortality, affecting approximately 1 in 380,000 to 1 in 1,000,000 people globally. It is caused by mutations that impair DNA repair.